Stenosis

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Pi-Cardia Successfully Treats First Patients with ShortCut™ Device

Thursday, January 7, 2021 - 4:00pm

ShortCut is the worlds first dedicated device designed to split the leaflets of a pre-existing valve to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk for coronary obstruction or compromised coronary access.

Key Points: 
  • ShortCut is the worlds first dedicated device designed to split the leaflets of a pre-existing valve to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk for coronary obstruction or compromised coronary access.
  • Using ShortCut we were able to treat two extremely complex patients with degenerated valves that needed a solution to prevent coronary obstruction after TAVR.
  • ShortCut is the latest addition to Pi-Cardias product offering, which includes the Leaflex device a standalone, non-implant-based treatment for patients with aortic stenosis.
  • As the number of patients with aortic stenosis continues to grow, both Shortcut and Leaflex may offer important new treatment options for both physicians and patients.

Vertos Medical Announces ASC Reimbursement Increase for the mild® Procedure

Tuesday, December 8, 2020 - 11:00am

Effective January 1, 2021, the national average ASC reimbursement for CPT 0275T will increase by 41%, from $2,803.35 to $3,941.14, in recognition of the device cost associated with the procedure.

Key Points: 
  • Effective January 1, 2021, the national average ASC reimbursement for CPT 0275T will increase by 41%, from $2,803.35 to $3,941.14, in recognition of the device cost associated with the procedure.
  • "The mild Procedure is ideally suited for an ASC setting and we are pleased that CMS has improved the reimbursement for these facilities.
  • We believe this will significantly increase patient access to the mild Procedure across the country," said Philip Macdonald, Vice President, Market Access & Reimbursement for Vertos Medical.
  • Vertos Medical Inc. is a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS).

OrbusNeich® Medical and P+F Products & Features® announce new partnership

Monday, November 9, 2020 - 11:00am

The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.

Key Points: 
  • The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.
  • The minimally invasive valve replaces the native aortic valve without the need for concomitant surgical removal.Both systemsare pending CE mark approval.
  • "This powerful partnership supports our strategic business directive to add important complementary structural heart devices to our coronary and peripheral portfolio.
  • OrbusNeich supplies medical devices to physicians in more than 60 countries.

OrbusNeich® Medical and P+F Products & Features® announce new partnership

Monday, November 9, 2020 - 11:00am

The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.

Key Points: 
  • The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.
  • The minimally invasive valve replaces the native aortic valve without the need for concomitant surgical removal.Both systemsare pending CE mark approval.
  • "This powerful partnership supports our strategic business directive to add important complementary structural heart devices to our coronary and peripheral portfolio.
  • OrbusNeich supplies medical devices to physicians in more than 60 countries.

Shockwave IVL Is Superior to Angioplasty in Severely Calcified Peripheral Artery Disease

Saturday, November 7, 2020 - 3:05pm

The largest randomized trial of severely calcified peripheral lesions, Disrupt PAD III found that IVL was also associated with a statistically significant reduction in diameter stenosis, arterial dissections and bail-out stenting versus PTA.

Key Points: 
  • The largest randomized trial of severely calcified peripheral lesions, Disrupt PAD III found that IVL was also associated with a statistically significant reduction in diameter stenosis, arterial dissections and bail-out stenting versus PTA.
  • The study enrolled 306 patients randomized between IVL and PTA at 45 sites in the United States, Germany, Austria and New Zealand.
  • In the IVL arm, 83 percent of patients were classified by the angiographic core lab as having severe calcification, with an average calcified lesion length of 129 millimeters.
  • Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Groundbreaking Endovascular Clinical Trial Results Announced at VIVA20

Friday, November 6, 2020 - 7:10pm

SAN JOSE, Calif., Nov. 6, 2020 /PRNewswire/ --VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the first five of ten highly anticipated late-breaking clinical trial results presented at the VIVA20 virtual meeting.

Key Points: 
  • SAN JOSE, Calif., Nov. 6, 2020 /PRNewswire/ --VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the first five of ten highly anticipated late-breaking clinical trial results presented at the VIVA20 virtual meeting.
  • Below are highlights of this afternoon's late-breaking clinical trial presentations:
    This IN.PACT Global Study is the first presentation of 5-year data from a real-world, drug-coated balloon (DCB) global study.
  • The mean lesion length in this clinical cohort was 12.10 9.54cm, with 18.0% in-stent restenosis, 35.5% total occlusions, and 68.7% calcification.
  • Since the results of this real-world study were first published, safety and effectiveness through 5 years have been sustained.

Biliary Stent Market Research Report by Type, by End User, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

Wednesday, November 4, 2020 - 1:50pm

Based on Application, the Biliary Stent Market studied across Benign Biliary Strictures, Biliary Leaks, and Malignant Obstruction.

Key Points: 
  • Based on Application, the Biliary Stent Market studied across Benign Biliary Strictures, Biliary Leaks, and Malignant Obstruction.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Biliary Stent Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biliary Stent Market?
  • What are the modes and strategic moves considered suitable for entering the Global Biliary Stent Market?

Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

Wednesday, October 7, 2020 - 7:00am

Inositec , a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.

Key Points: 
  • Inositec , a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.
  • Currently CEO of New Amsterdam Pharma, Dr. Davidson was previously the founding CEO and Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk.
  • We are truly honored to have Michael join our Board of Directors.
  • Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions.